Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Prostate Cancer
Interventions: ZD4054 15 mg, Placebo, ZD4054 10 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 7
States / cities: Tucson, Arizona • Los Angeles, California • Gainsville, Florida + 4 more

Conditions: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Benralizumab Arm A, Benralizumab Arm B, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 138
States / cities: Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 114 more

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 50
States / cities: Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more

Conditions: Migraine Prophylaxis
Interventions: E2007, Placebo; Drug · Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Oceanside, California • Santa Monica, California • Tampa, Florida + 6 more

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine or control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Diabetic Foot Ulcers
Interventions: DSC127, placebo vehicle gel; Drug
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 25
States / cities: Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more

Conditions: Aging, Emotions, Parkinson Disease
Interventions: Anterior cingulate cortex activation, Primary auditory cortex activation; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Migraine, Migraine Disorders
Interventions: sumatriptan succinate/naproxen sodium; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 35
States / cities: Chandler, Arizona • Irvine, California • Redondo Beach, California + 30 more

Conditions: Obesity or Overweight, Type 2 Diabetes Mellitus
Interventions: Placebo, Enicepatide; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 45
States / cities: Guntersville, Alabama • Tucson, Arizona • Irvine, California + 41 more

Conditions: Keratoconjunctivitis Sicca
Interventions: Hydroeye, Inactive Capsule; Dietary Supplement · Other
Lead sponsor: Virginia Eye Consultants; Other
Eligibility: 40 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Houston, Texas • Norfolk, Virginia

Conditions: Seasonal Allergic Rhinitis
Interventions: ACT-129968, Cetirizine, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Face Injuries, Hand Injuries, Craniofacial Injuries, Upper Extremity Injuries, Facial Injuries, Facial Deformity
Interventions: Combined Craniomaxillofacial and Upper Extremity Allotransplantation; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: tiotropium 5mcg/day, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Riverside, California + 16 more

Conditions: Healthy
Interventions: AZD5847, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Asthma
Interventions: placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 18
States / cities: Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more

Conditions: Stroke
Interventions: Exercise Program + Respiratory Strength Training, Exercise Program + Respiratory Relaxation Training; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 95 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Smallpox
Interventions: IMVAMUNE; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 56 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Orlando, Florida • Iowa City, Iowa • Lexington, Kentucky + 1 more

Conditions: Actinic Keratosis
Interventions: PEP005 Gel, Vehicle gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 19
States / cities: Los Angeles, California • Oceanside, California • San Diego, California + 16 more

Conditions: Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis
Interventions: TTAX03, Saline (NaCl 0,9 %) (placebo); Biological
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Berkeley, California • Deerfield Beach, Florida • Chaska, Minnesota + 6 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Pirfenidone, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Type 2 Diabetes Mellitus
Interventions: TTP054, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 19
States / cities: Chula Vista, California • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Generalized Anxiety Disorder
Interventions: SEP-363856, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 38
States / cities: Huntsville, Alabama • Phoenix, Arizona • Culver City, California + 29 more

Conditions: Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions: Alfuzosin (SL770499); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older · Male only
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 35
States / cities: Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more

Conditions: Osteoarthritis
Interventions: Ketoprofen Topical Patch , 20%; Drug
Lead sponsor: Alkemira SA; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

Emotion Study/Substudy: Flexible Brain Study

Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

Craniomaxillofacial and Upper Extremity Allotransplantation

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Augmenting a Post-Stroke Wellness Program With Respiratory Muscle Training

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Clinical Trial in Males With BPH (Enlarged Prostate)

Ketoprofen Topical Patch, 20% in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee